6-amino-2-[(1-naphthylmethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one

This compound is a small molecule inhibitor characterized by the chemical structure of an imidazoquinazoline derivative. It has been identified as a potent inhibitor of tRNA-Guanine Transglycosylase (TGT), an enzyme linked to the pathogenicity of Shigella bacteria. Additionally, it has shown inhibitory activity against viral 3C-like proteases such as those involved in SARS-CoV and related coronaviruses, suggesting potential antiviral properties. The mechanism involves binding to critical residues in the protease active site or TGT enzyme via hydrogen bonding networks that stabilize inhibition. This compound was studied primarily for research and drug repositioning purposes but does not have approved clinical indications or marketed formulations. No clinical trials or regulatory approvals are currently associated with this molecule.